TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety

DATE: 24 April 2014

RESEARCH QUESTION

What is the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy?

KEY MESSAGE

No relevant conference abstracts were identified regarding the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy.

METHODS

A limited literature search was conducted on key resources including PubMed, EMBASE, The Cochrane Library (2014, Issue 3), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2012 and April 16, 2014. Internet links were provided, where available.

Selection was limited to conference abstracts to capture emerging evidence regarding the retreatment of patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior DAA plus PR therapy.
RESULTS

No relevant conference abstracts were identified regarding the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy.

OVERALL SUMMARY OF FINDINGS

No relevant conference abstracts were identified regarding the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy, therefore no summary can be provided.

REFERENCES SUMMARIZED

Health Technology Assessments
No conference abstracts identified.

Systematic Reviews and Meta-analyses
No conference abstracts identified.

Randomized Controlled Trials
No conference abstracts identified.

Non-Randomized Studies
No conference abstracts identified.

PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca